Journal for ImmunoTherapy of Cancer
短名 | J Immunother Cancer |
Journal Impact | 10.17 |
国际分区 | ONCOLOGY(Q1) |
期刊索引 | SCI Q1中科院 1 区 |
ISSN | 2051-1426 |
h-index | 117 |
国内分区 | 医学(1区)医学免疫学(1区)医学肿瘤学(2区) |
Top期刊 | 是 |
涉及主题 | 医学生物遗传学内科学免疫学免疫系统癌症化学癌症研究生物化学免疫疗法病理肿瘤科抗原体外T细胞细胞毒性T细胞CD8型受体外科基因抗体肿瘤细胞 |
出版信息 | 出版商: BMJ Publishing Group,出版周期: ,期刊类型: journal |
基本数据 | 创刊年份: 2013,原创研究文献占比: 92.14%,自引率:2.90%, Gold OA占比: 98.98% |
平均审稿周期 | 18 Weeks |
期刊引文格式
这些示例是对学术期刊文章的引用,以及它们应该如何出现在您的参考文献中。
并非所有期刊都按卷和期组织其已发表的文章,因此这些字段是可选的。有些电子期刊不提供页面范围,而是列出文章标识符。在这种情况下,使用文章标识符而不是页面范围是安全的。
只有1位作者的期刊
有2位作者的期刊
有3位作者的期刊
有5位以上作者的期刊
书籍引用格式
以下是创作和编辑的书籍的参考文献的示例。
学位论文引用格式
网页引用格式
这些示例是对网页的引用,以及它们应该如何出现在您的参考文献中。
专利引用格式
最新文章
scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC
2024-9-1
Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
2024-9-1
Jeffrey S Weber, MD, PhD (1952–2024): in memoriam to discovery, friendship and family
2024-9-1
Intratumoral CXCL13<sup>+</sup>CD160<sup>+</sup>CD8<sup>+</sup>T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer
2024-9-1
Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway
2024-9-1
Non-invasive multimodal CT deep learning biomarker to predict pathological complete response of non-small cell lung cancer following neoadjuvant immunochemotherapy: a multicenter study
2024-9-1
Endosialin-positive CAFs promote hepatocellular carcinoma progression by suppressing CD8<sup>+</sup>T cell infiltration
2024-9-1
Circumventing resistance within the Ewing sarcoma microenvironment by combinatorial innate immunotherapy
2024-9-1
Durability of response to immune checkpoint blockade following treatment discontinuation and efficacy of rechallenge in advanced Merkel cell carcinoma
2024-9-1
Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models
2024-9-1
Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade
2024-9-1
MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers
2024-9-1
Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC
2024-8-1
Five-year follow-up of neoadjuvant PD-1 inhibitor (sintilimab) in non-small cell lung cancer
2024-8-1
Targeting<i>Gsk3a</i>reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma
2024-8-1
Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study
2024-8-1
Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy
2024-8-1
Neutralizing IL-38 activates γδ T cell-dependent antitumor immunity and sensitizes for chemotherapy
2024-8-1
Targeting TNFRSF25 by agonistic antibodies and multimeric TL1A proteins co-stimulated CD8<sup>+</sup>T cells and inhibited tumor growth
2024-8-1
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)
2024-8-1
S100A9 and HMGB1 orchestrate MDSC-mediated immunosuppression in melanoma through TLR4 signaling
2024-8-1
Treatment with oncolytic vaccinia virus infects tumor-infiltrating regulatory and exhausted T cells
2024-8-1
NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors
2024-8-1
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study
2024-8-1
Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity
2024-8-1
Immune checkpoint blockade: timing is everything
2024-8-1
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment
2024-8-1
NKG2C/<i>KLRC2</i>tumor cell expression enhances immunotherapeutic efficacy against glioblastoma
2024-8-1
Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy
2024-8-1
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab
2024-8-1
An IL-7 fusion protein targeting EDA fibronectin upregulates TCF1 on CD8+ T-cells, preferentially accumulates to neoplastic lesions, and boosts PD-1 blockade
2024-8-1
Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus
2024-8-1
ALOX5 contributes to glioma progression by promoting 5-HETE-mediated immunosuppressive M2 polarization and PD-L1 expression of glioma-associated microglia/macrophages
2024-8-1
Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer
2024-8-1
Inclusion, characteristics, and reporting of older adults in FDA registration studies of immunotherapy, 2018–2022
2024-8-1
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab
2024-8-1
EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses
2024-8-1
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors
2024-8-1
Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer
2024-8-1
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
2024-8-1
EphA3 CAR T cells are effective against glioblastoma in preclinical models
2024-8-1
Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling
2024-7-1
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma
2024-7-1
Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies
2024-7-1
Cantharidin overcomes IL-2Rα signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species
2024-7-1
Merkel cell carcinoma refractory to anti-PD(L)1: utility of adding ipilimumab for salvage therapy
2024-7-1
IFNγ mediates the resistance of tumor cells to distinct NK cell subsets
2024-7-1
Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma
2024-7-1
Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?
2024-7-1
Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort
2024-7-1
帮你贴心管理全部的文献
研飞ivySCI,高效的论文管理
投稿经验分享
分享我的经验,帮你走得更远